API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
https://www.globenewswire.com/news-release/2024/08/12/2928730/0/en/Boundless-Bio-Provides-Business-Updates-Focused-on-Key-Value-Drivers-and-Reports-Second-Quarter-2024-Financial-Results.html
https://www.globenewswire.com/news-release/2024/08/12/2928472/0/en/Outlook-Therapeutics-to-Present-at-the-H-C-Wainwright-4th-Annual-Ophthalmology-Virtual-Conference.html
https://www.globenewswire.com/news-release/2024/07/30/2921084/0/en/Outlook-Therapeutics-to-Present-at-the-BTIG-Virtual-Biotechnology-Conference-2024.html
https://www.globenewswire.com/news-release/2024/07/18/2915001/0/en/Junshi-Biosciences-Announces-the-Acceptance-of-the-Supplemental-New-Drug-Application-for-Toripalimab-Combined-with-Bevacizumab-for-the-First-Line-Treatment-of-Advanced-Hepatocellul.html
https://www.globenewswire.com/news-release/2024/07/08/2909641/0/en/Outlook-Therapeutics-Announces-UK-MHRA-Marketing-Authorization-of-LYTENAVA-bevacizumab-gamma-for-the-Treatment-of-Wet-AMD.html
https://www.globenewswire.com/news-release/2024/06/20/2901630/0/en/Tempest-Unveils-New-Survival-Data-for-Amezalpat-TPST-1120-in-Randomized-First-Line-HCC-Study-Demonstrating-a-Six-Month-Improvement-over-Control-Arm.html
https://www.globenewswire.com/news-release/2024/06/12/2897253/0/en/Junshi-Biosciences-Announces-Phase-3-Study-of-Toripalimab-Combined-with-Bevacizumab-for-the-First-line-Treatment-of-Advanced-Hepatocellular-Carcinoma-Meets-Primary-Endpoint.html
https://www.prnewswire.com/news-releases/bio-thera-solutions-receives-positive-chmp-opinion-for-avzivi-bevacizumab-a-biosimilar-referencing-avastin-302161771.html
https://www.globenewswire.com/news-release/2024/05/28/2889004/0/en/Outlook-Therapeutics-Receives-European-Commission-Marketing-Authorization-for-LYTENAVA-bevacizumab-gamma-for-the-Treatment-of-Wet-AMD.html
https://www.globenewswire.com/news-release/2024/05/15/2882970/0/en/Outlook-Therapeutics-Reports-Financial-Results-for-Second-Quarter-Fiscal-Year-2024-and-Provides-Corporate-Update.html
https://www.globenewswire.com/news-release/2024/05/15/2882430/0/en/Abstract-on-Phase-2-Study-with-IMUNON-s-IMNN-001-Plus-Bevacizumab-Accepted-for-Presentation-at-the-American-Society-of-Clinical-Oncology-Annual-Meeting.html
https://www.indianpharmapost.com/news/dr-reddys-laboratories-launches-versavo-in-the-uk-15415
https://www.drreddys.com/cms/cms/sites/default/files/2024-03/Press%20release%20-%20Dr.%20Reddy%27s%20b-mab%20launch%20UK.pdf
https://www.globenewswire.com//news-release/2024/02/27/2836041/0/en/Memorial-Sloan-Kettering-Cancer-Center-Now-Enrolling-Patients-in-Phase-1-2-Clinical-Trial-of-IMUNON-s-IMNN-001-in-Combination-with-Bevacizumab-in-Advanced-Ovarian-Cancer.html
https://www.indianpharmapost.com/news/biocon-biologics-partners-with-sandoz-australia-for-biosimilars-trastuzumab-and-bevacizumab-15257
https://www.prnewswire.com/news-releases/fda-approves-bio-thera-solutions-avzivi-bevacizumab-tnjn-a-biosimilar-referencing-avastin-302009433.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761198
https://endpts.com/outlook-to-conduct-another-trial-for-wet-amd-drug-cara-strikes-new-royalty-deal/
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-october-25-2023-66768.pdf
https://www.globenewswire.com//news-release/2023/10/18/2762368/0/en/IMUNON-Announces-First-Patient-enrolled-in-Phase-1-2-Clinical-Trial-of-IMNN-001-in-Combination-with-bevacizumab-in-Advanced-Ovarian-Cancer.html
https://www.prnewswire.com/news-releases/ascletis-announces-completion-of-enrollment-of-120-patients-in-the-phase-iii-clinical-trial-of-fasn-inhibitor-asc40-combined-with-bevacizumab-for-treatment-of-recurrent-glioblastoma-301937564.html
https://www.onclive.com/view/maintenance-mirvetuximab-soravtansine-plus-bevacizumab-under-exploration-in-fr-ovarian-cancer
https://www.onclive.com/view/trifluridine-tipiracil-plus-bevacizumab-provides-potential-first-line-alternative-to-bevacizumab-capecitabine-in-mcrc
https://endpts.com/fda-approves-taihos-lonsurf-with-bevacizumab-for-third-line-metastatic-colorectal-cancer/
https://www.prnewswire.com/news-releases/fda-approves-lonsurf-trifluridinetipiracil-in-combination-with-bevacizumab-for-adult-patients-with-metastatic-colorectal-cancer-mcrc-301892077.html
https://www.onclive.com/view/nox-a12-plus-bevacizumab-and-radiotherapy-shows-sustained-survival-in-glioblastoma
https://www.clinicaltrialsarena.com/news/tvardi-first-patients-liver-cancer/
https://www.prnewswire.com/news-releases/the-china-nmpa-approves-tyvyt-sintilimab-injection-in-combination-with-bevacizumab-and-chemotherapy-in-patients-with-egfr-mutated-non-squamous-nsclc-who-progressed-after-egfr-tki-therapy-301819664.html
https://www.prnewswire.com/news-releases/taiho-oncology-and-servier-announce-publication-in-the-new-england-journal-of-medicine-of-pivotal-phase-3-data-for-trifluridinetipiracil-lonsurf-in-combination-with-bevacizumab-in-patients-with-refractory-metastatic-colorectal-301815323.html
https://health.economictimes.indiatimes.com/news/pharma/biocon-biologics-facility-gets-eu-gmp-certification-for-bevacizumab/99851350
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-19-2023-50304.pdf
https://www.ema.europa.eu/en/documents/overview/vegzelma-epar-medicine-overview_en.pdf
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/usfda-issues-crl-for-bevacizumab-license-application-moved-by-viatris-biocon/articleshow/97843998.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://www.biopharmadive.com/news/roche-tecentriq-avastin-adjuvant-liver-cancer-phase-3/640755/
https://www.clinicaltrialsarena.com/news/bexion-colorectal-carcinoma-therapy/
https://www.globenewswire.com/news-release/2022/12/16/2575333/0/en/Adagene-Announces-Clinical-Trial-Collaboration-to-Evaluate-Anti-CTLA-4-SAFEbody-ADG126-in-Combination-with-Roche-s-Standard-of-Care-for-First-Line-Advanced-Liver-Cancer.html
https://www.prnewswire.com/news-releases/enterome-completes-patient-enrollment-of-phase-2-rosalie-study-evaluating-its-lead-immunotherapy-eo2401-in-recurrent-glioblastoma-301700145.html
https://www.globenewswire.com//news-release/2022/12/07/2569082/0/en/Replimune-Enters-into-Clinical-Collaboration-Agreement-with-Roche-for-the-Development-of-RP3-In-Colorectal-Cancer-and-Hepatocellular-Carcinoma.html
https://www.prnewswire.com/news-releases/brand-institute-partners-on-brand-name-development-for-fda-approved-biologic-medication-for-the-treatment-of-cancer-301652750.html
https://www.prnewswire.com/news-releases/leap-therapeutics-announces-first-patient-enrolled-in-defiance-study-of-dkn-01-for-the-treatment-of-colorectal-cancer-patients-301649992.html
https://www.businesswire.com/news/home/20220927006146/en/Celltrion-USA-Receives-U.S.-FDA-Approval-for-its-Oncology-Biosimilar-Vegzelma%C2%AE-bevacizumab-adcd-for-the-Treatment-of-Six-Types-of-Cancer
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761268